This article is more than 5 years old. Information may no longer be current.

Bausch Health acquires anti-itch drop under study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch Health Companies and Eton Pharmaceuticals announced that a subsidiary of Bausch Health has acquired the U.S. rights to Eton Pharmaceuticals investigational eye drop.

Once FDA-approved, the agent would be an over-the-counter preservative-free formulation for the treatment of ocular itching associated with allergic conjunctivitis, Bausch said in a press release.

EM-100 has been submitted to the FDA for review, according to the company press release.

Previously, Eton Pharmaceuticals reported positive results from a phase 3 trial where the eye drop showed statistically significant superiority to placebo and no adverse events and demonstrated noninferiority to a comparator product for ocular itching.